La integración de la cirugía y el tratamiento quimioterápico en el cáncer de vejiga infiltrante |
| |
| Authors: | Rafael Sánchez-Salas Gemma I. Duque Ruiz John Watson Eugenio Rocha Eric Barret Xavier Cathelineau Francois Rozet Marc Galiano Guy Vallancien |
| |
| Affiliation: | 1. Departamento de Urología, Institut Montsouris, Université Paris Descartes, París, Francia;2. Servicio de Urología, Hospital Universitario 12 Octubre, Madrid, España;1. Servicio de Urología, Fundación Instituto Valenciano de Urología (FIVO), Valencia, España;2. Departamento de Estadística e Investigación Operativa, Facultad de Matemáticas, Universidad de Almería, Almería, España;3. Servicio de Anatomía Patológica, FIVO, Valencia, España;1. Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center (CUCS), Guadalajara, Jalisco, Mexico;1. Departamento de Urología, Fundación Instituto Valenciano de Oncología, Valencia, España;2. Department of Surgery, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia;3. Young Urology Researchers Organisation (YURO), Melbourne, Victoria, Australia;4. Departamento de Patología, Fundacion Instituto Valenciano de Oncología, Valencia, España |
| |
| Abstract: | IntroductionTreating patients with invasive transitional cell carcinoma of the bladder remains difficult due to the multiple biological behaviour patterns found in this disease. There is still controversy regarding the use of systemic treatment in invasive bladder carcinoma and the ideal moment for launching perioperative chemotherapy. We present an overview of current trends for systemic treatment of invasive bladder carcinoma.Material and methodsUsing MEDLINE, we reviewed relevant English and Spanish language literature published during the last five years, with “chemotherapy in bladder cancer” as keywords. We selected randomized trials, meta-analyses and clinical trials.ResultsWe obtained a total of 241 articles. Thirty-one of them referred to neoadjuvant and adjuvant chemotherapy in invasive bladder cancer. We classified the articles in three different groups neoadjuvant, adjuvant and neoadjuvant plus chemotherapy. All of that information is displayed in the tables within the text.ConclusionsA multidisciplinary approach to the treatment of invasive bladder cancer is essential to guarantee adequate oncological control. A detailed evaluation and proper selection of each patient is fundamental in determining the best moment to start chemotherapy. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
